Related Experiment Video
Updated: Mar 17, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients
Hironori Uematsu1, Kazuto Yamashita1, Susumu Kunisawa1
1Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan.
Background:
The quantitative effect of multidrug-resistant bacterial infections on real-world health care resources is not clear. This study aimed to estimate the burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in pneumonia inpatients in Japan.
Methods:
Using a nationwide administrative claims database, we analyzed pneumonia patients who had been hospitalized in 1,063 acute care hospitals. Patients who received anti-MRSA drugs were categorized into an anti-MRSA drug group, and the remaining patients comprised the control group. We estimated the burden of length of stay, in-hospital mortality, total antibiotic agent costs, and total hospitalization costs. Risk adjustments were conducted using propensity score matching.
Results:
The study sample comprised 634 patients administered anti-MRSA drugs and 87,427 control patients. In propensity score-matching analysis (1 to 1), the median length of stay, antibiotic costs, and hospitalization costs of the anti-MRSA drug group were significantly higher than those of the control group (21 days vs 14 days [P < .001], $756 vs $172 [P < .001] and $8,741 vs $5,063 [P < .001], respectively); the attributable excess of these indicators were 9.0 ± 1.6 days, $1,044 ± $101, and $5,548 ± $580, respectively.
Conclusions:
These findings may serve as a reference to support further research on multidrug-resistant bacterial infections and eventually inform policy formulation.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia significantly increases healthcare costs and length of hospital stay in Japan. This study quantifies the substantial burden of MRSA infections on healthcare resources.
Area of Science:
- Healthcare Economics
- Infectious Diseases
- Public Health
Background:
- The economic impact of multidrug-resistant bacterial infections on healthcare systems remains unclear.
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen contributing to hospital-acquired infections.
- Pneumonia caused by MRSA presents a particular challenge in inpatient settings.
Purpose of the Study:
- To estimate the real-world healthcare resource burden associated with MRSA infections in hospitalized pneumonia patients in Japan.
- To quantify the excess length of stay, mortality, and costs attributable to MRSA pneumonia.
- To provide data for policy formulation regarding antimicrobial resistance.
Main Methods:
- Analysis of a nationwide administrative claims database from 1,063 acute care hospitals in Japan.
- Inclusion of pneumonia patients, categorized into anti-MRSA drug users and a control group.
- Propensity score matching (1:1) to adjust for confounding factors and estimate attributable costs and length of stay.
Main Results:
- The study included 634 patients in the anti-MRSA group and 87,427 in the control group.
- MRSA pneumonia patients experienced significantly longer hospital stays (median 21 vs 14 days) and higher costs ($8,741 vs $5,063).
- Attributable excess costs were $5,548 ± $580 per patient, with an additional 9.0 ± 1.6 days of hospitalization.
Conclusions:
- MRSA pneumonia imposes a substantial economic and resource burden on Japanese hospitals.
- Findings highlight the need for effective strategies to combat MRSA infections and manage healthcare costs.
- This research provides valuable data for future studies and policy development concerning multidrug-resistant organisms.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:29Pneumonia II: Pathophysiology
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.